Premium
Receptor pharmacogenetics: relevance to CNS syndromes
Author(s) -
Shaikh Sanober,
Kerwin Robert W.
Publication year - 2002
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1046/j.1365-2125.2002.01679.x
Subject(s) - pharmacogenetics , drug , drug response , pharmacology , medicine , adverse effect , drug reaction , bioinformatics , relevance (law) , neurotransmitter systems , clinical significance , intensive care medicine , biology , receptor , genetics , genotype , gene , political science , law
Pharmacogenetic research dedicated to the investigation of inherited factors that influence drug response has produced exciting results over the past decade. Adding to the knowledge that genetic variation in metabolic enzymes may cause drug‐related adverse reactions, recent studies indicate that variation in neurotransmitter receptors can also be the cause of treatment failure. In addition, recent studies have attempted to use genetic information for the prediction of treatment outcome. The aim of this review is to summarize the most significant findings in pharmacogenetic research in relation to CNS drugs and to outline how these studies could lead to the individualization of drug treatment.